SULFADIAZINE, SILVER


Synonyms	Altreet-ag Dermazin Flamazine Flammacerium Sildaflo Silvadene Silvazine Silver sulfadiazine Silver sulphadiazine Ssd af Sulfadiazine silver Sulfadiazine silver salt Sulfadiazine, silver Sulfadiazinum argentum Thermazene
Status
Molecule Category	Salt-form
UNII	W46JY43EJR
EPA CompTox	DTXSID4048646

Structure


InChI Key	UEJSSZHHYBHCEL-UHFFFAOYSA-N
Smiles	Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Ag+]
InChI	InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C10H9AgN4O2S
Molecular Weight	357.14
AlogP	0.86
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	3.0
Polar Surface Area	97.97
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	17.0

Pharmacology

Mechanism of Action	Action	Reference
Bacterial dihydropteroate synthase inhibitor	INHIBITOR	DailyMed

Cross References

Resources	Reference
ChEBI	9142
ChEMBL	CHEMBL1382627
DrugBank	DB05245
FDA SRS	W46JY43EJR
PharmGKB	PA164744951
SureChEMBL	SCHEMBL15633

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).